Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HTT | P42858 | 1/20 | 0.37 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.37 |
| ▸ | MEN1 | O00255 | 1/20 | 0.35 |
| ▸ | MAPT | P10636 | 1/20 | 0.35 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.35 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.35 |
| ▸ | HSD17B3 | P37058 | 1/20 | 0.32 |
| ▸ | CYP1A2 | P05177 | 2/20 | 0.31 |
| ▸ | CYP2A6 | P11509 | 2/20 | 0.31 |
| ▸ | METAP1 | P53582 | 1/20 | 0.31 |
| ▸ | PARP10 | Q53GL7 | 1/20 | 0.30 |
| ▸ | PARP11 | Q9NR21 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL17190968 | 0.83 | — | — | |
| SCHEMBL3696049 | 0.72 | EPHX2 (0.42) | HTTEPHX2MEN1MAPTKMT2A | |
| SCHEMBL21311949 | 0.72 | METAP1 (0.39) | EPHX2MAPTTDP1HSD17B3CYP1A2 | |
| SCHEMBL928214 | 0.71 | EPHX2 (0.35) | HTTEPHX2MEN1MAPTKMT2A | |
| SCHEMBL468939 | 0.71 | CTSL (0.42) | EPHX2MEN1MAPTKMT2ACYP1A2 | |
| SCHEMBL1120940 | 0.70 | RYR2 (0.41) | HTTMEN1MAPTKMT2ATDP1 | |
| SCHEMBL402071 | 0.70 | METAP1 (0.42) | HTTEPHX2MEN1MAPTKMT2A | |
| SCHEMBL12936026 | 0.68 | HSD17B3 (0.48) | HTTEPHX2MEN1MAPTKMT2A | |
| SCHEMBL31414376 | 0.68 | EPHX2 (0.33) | HTTEPHX2MEN1MAPTKMT2A | |
| SCHEMBL11339018 | 0.68 | ALDH1A1 (0.38) | EPHX2MEN1MAPTKMT2ACYP1A2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3875151-B1 | ALPHA-METHYL-SUBSTITUTED DIAZABICYCLO [4.3.1] DECANE DERIVATES FOR TREATMENT OF PSYCHIATRIC DISORDERS | UNIV DARMSTADT TECH (DE) | 2023-09-20 | — | — | EP | disclosed |
| EP-3674757-B1 | POLYMERIZABLE LIQUID CRYSTAL MATERIAL, POLYMERIZABLE LIQUID CRYSTAL COMPOSITION, POLYMER, OPTICAL FILM, OPTICAL ANISOTROPIC BODY, POLARIZER, ANTIREFLECTIVE FILM, DISPLAY DEVICE AND METHOD FOR MANUFACTURING POLYMERIZABLE LIQUID CRYSTAL COMPOSITION | ZEON CORP (JP) | 2022-04-20 | — | — | EP | disclosed |
| EP-3875151-A1 | ALPHA-METHYL-SUBSTITUTED DIAZABICYCLO [4.3.1] DECANE DERIVATES FOR TREATMENT OF PSYCHIATRIC DISORDERS | Technische Universität Darmstadt (DE) | 2021-09-08 | — | — | EP | disclosed |
| EP-3097103-B1 | DIAZABICYCLO[4.3.1]DECANE DERIVATIVES FOR TREATMENT OF PSYCHIATRIC DISORDERS | MAX-PLANCK-GESELLSCHAFT ZUR FÖRDERUNG DER WSS (DE) | 2017-11-15 | — | — | EP | disclosed |
| US-5459142-A | Autoimmune disease, atherosclerosis, antiischemic agents and nephritis | OTSUKA PHARMACEUTICAL CO., LTD. (JP) | 1995-10-17 | — | — | US | disclosed |
| EP-0670831-A1 | QUINOXALINE DERIVATIVE AS ANTIDIABETIC AGENT | OTSUKA PHARMACEUTICAL CO., LTD. (JP) | 1995-09-13 | — | — | EP | disclosed |
| WO-1995009159-A1 | QUINOXALINE DERIVATIVE AS ANTIDIABETIC AGENT | OTSUKA PHARMACEUTICAL COMPANY, LIMITED (JP) | 1995-04-06 | — | — | WO | disclosed |
| EP-0511879-B1 | Pyrazine derivatives | OTSUKA PHARMA CO LTD (JP) | 1995-03-22 | — | — | EP | disclosed |
| EP-0511879-A1 | Pyrazine derivatives | OTSUKA PHARMACEUTICAL CO., LTD. (JP) | 1992-11-04 | — | — | EP | disclosed |